The multi-institutional phase I study: Disadvantages without advantages?

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 1915-1916

  Verweij, Jaap ^a   Eskens, Ferry ^a   De Jonge, Maja ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CANCER RISK; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG INDUSTRY; EDITORIAL; HUMAN; PRIORITY JOURNAL; SOLID TUMOR; METHODOLOGY; MULTICENTER STUDY; NOTE; PHASE 1 CLINICAL TRIAL;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC;

EID: 42949103049     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7099     Document Type: Editorial

References (8)

1. Dowlati A, Manda S, Gibbons J, et al: Multi-institutional phase I trials of anticancer agents. J Clin Oncol 26:1926-1931, 2008
2. Roberts TG, Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase I clinical trials. JAMA 292:2130-2140, 2004
3. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase I oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
4. Cheng JD, Hitt J, Koczwara B, et al: Impact of quality of life on patients expectations regarding phase I clinical trials. J Clin Oncol 18:421-428, 2000
5. Booth CM, Calvert H, Giaccone G, et al: Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 44:19-24, 2008
6. Booth CM, Calvert AH, Giaccone G, et al: Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 44:25-29, 2008
7. Ratain MJ, Humphrey RW, Gordon GB, et al: Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer (in press)
8. Tolcher AW, Takimoto CH, Rowinsky EK: The multifunctional, multi-institutional, and sometimes even global phase I study: A better life for phase I evaluations or just "living large"? J Clin Oncol 20:4276-4278, 2002